| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 735.07M | 846.50M | 933.07M | 636.46M | 632.57M | 512.78M |
| Gross Profit | 265.88M | 344.96M | 407.09M | 202.14M | 198.74M | 135.76M |
| EBITDA | 89.84M | 170.68M | 234.18M | -209.54M | 41.78M | -218.17M |
| Net Income | -43.05M | 47.38M | 84.16M | -297.73M | -101.46M | -371.38M |
Balance Sheet | ||||||
| Total Assets | 836.78M | 939.13M | 944.39M | 901.38M | 1.27B | 1.47B |
| Cash, Cash Equivalents and Short-Term Investments | 331.90M | 354.52M | 304.31M | 226.08M | 223.84M | 299.21M |
| Total Debt | 172.62M | 185.83M | 206.07M | 217.02M | 280.24M | 361.10M |
| Total Liabilities | 396.45M | 430.26M | 492.63M | 540.03M | 586.66M | 659.19M |
| Stockholders Equity | 478.86M | 553.83M | 522.28M | 438.26M | 737.46M | 838.63M |
Cash Flow | ||||||
| Free Cash Flow | 57.38M | 114.10M | 148.21M | 66.16M | 9.10M | -18.73M |
| Operating Cash Flow | 75.98M | 135.92M | 158.92M | 76.28M | 22.25M | -4.22M |
| Investing Cash Flow | -18.16M | -21.03M | -8.64M | -23.07M | -15.74M | 47.82M |
| Financing Cash Flow | -58.08M | -65.18M | -73.07M | -57.26M | -79.84M | -86.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$372.44M | 11.68 | 4.28% | 7.10% | -2.88% | -22.83% | |
71 Outperform | HK$652.07M | 7.90 | 5.33% | 8.21% | 0.47% | 50.46% | |
65 Neutral | HK$450.00M | 19.40 | 5.24% | 4.44% | 20.85% | -66.81% | |
56 Neutral | HK$829.16M | 5.69 | 30.40% | ― | 2.30% | ― | |
55 Neutral | HK$303.64M | 11.53 | 3.40% | 3.75% | 9.07% | 8.95% | |
54 Neutral | HK$341.67M | -7.31 | -8.40% | 3.16% | -21.31% | -149.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
New Century Healthcare Holding Co. Ltd. announced the termination of a voting agreement between its chairman and CEO, Mr. Jason Zhou, and substantial shareholder Ms. Liang Yanqing. This agreement, initially established in 2016 and extended to 2028, allowed Ms. Liang to follow Mr. Zhou’s voting directions. The termination, effective November 25, 2025, concludes all legal obligations under the agreement, allowing Ms. Liang independent voting rights. This change may impact the company’s governance dynamics and is a significant shift in shareholder relations.